ArticleInternational journal of obesity (2005)2026
Association between adherence to EAT-Lancet diet and risk of sarcopenia and sarcopenic obesity in adults.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protein Consumption and Cognitive Health in Aging: Associations with Sarcopenia and Dietary Options, a Narrative Review.Nutrients · 2026Review
- Associations between Mediterranean diet adherence and body composition and metabolic outcomes in older adults at risk of sarcopenic obesity.BMC geriatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the association between adherence to the EAT-Lancet diet and the prevalence of sarcopenia as well as sarcopenic obesity in adults.
methodsThis study included 9672 participants from the National Health and Nutrition Examination Survey. We developed an EAT-Lancet score based on 24-hour dietary recall data and grouped the participants according to the quartiles of this score. Weighted multivariate logistic regression models and restricted cubic splines were employed to assess the association between the EAT-Lancet diet and sarcopenia and sarcopenic obesity. Additionally, mediation analysis was conducted to evaluate the mediating role of inflammatory biomarkers in this relationship.
resultsAmong the 9672 participants, 910 (9.41%) were identified with sarcopenia, and 607 (6.28%) were identified with sarcopenic obesity. After adjusting for potential confounders, the odds ratios (OR) and 95% confidence intervals (CI) for sarcopenia and sarcopenic obesity in the highest quartile groups were 0.72 (0.54-0.95) and 0.58 (0.42-0.82), respectively, compared to those in the lowest quartile group. A 10-point increase in the EAT-Lancet diet score was significantly associated with a reduced risk of sarcopenia and sarcopenic obesity, with OR (95% CI) of 0.90 (0.84-0.98) and 0.86 (0.79-0.93), respectively. Furthermore, white blood cell count demonstrated the strongest mediating effect on this association, followed by C-reactive protein, systemic inflammation response index and systemic inflammatory index.
conclusionOur study indicated that adherence to the EAT-Lancet diet was associated with a lower risk of sarcopenia and sarcopenic obesity, with this association partially mediated by inflammatory biomarkers.
Indexed as
Identifiers
41214306What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.